[Federal Register: September 8, 2006 (Volume 71, Number 174)]
[Notices]               
[Page 53104-53105]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr08se06-56]                         

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

 
Prospective Grant of Exclusive License: Insecticide-Impregnated 
Bednet

AGENCY: Technology Transfer Office, Centers for Disease Control and 
Prevention (CDC), Department of Health and Human Services.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is a notice in accordance with 35 U.S.C. 209(e) and 37 
CFR 404.7(a)(1)(i) that the Centers for Disease

[[Page 53105]]

Control and Prevention (CDC), Technology Transfer Office, Department of 
Health and Human Services (DHHS), is contemplating the grant of a 
limited field of use, exclusive license in India to practice the 
inventions embodied in the patent referred to below to Molecular 
Diagnostic Laboratory, having a place of business in Lucknow, India. 
The patent rights in these inventions have been assigned to the 
government of the United States of America. The patent(s) to be 
licensed are:
    US 6,896,892 B2 entitled ``Insecticide-Impregnated Fabric and 
Method of Production,'' issue date 05.24.2005. CDC Technology ID No. I-
008-99.
    Status: Issued.
    Issue Date: 05.24.2005
    The prospective exclusive license will be royalty-bearing and will 
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7.
    Technology: This technology provides a new insecticide-impregnated 
fabric and method of production for bednets.

SUPPLEMENTARY INFORMATION: In accordance with 35 U.S.C. 209(e) and 37 
CFR 404.7(a)(1)(i), CDC is providing public notice of its intention to 
grant an exclusive license. CDC will accept written comments concerning 
this notice for 30 days. Applications for a license filed in response 
to this notice will be treated as objections to the grant of the 
contemplated license. Only written comments and/or applications for a 
license which are received by CDC within thirty days of this notice 
will be considered. Comments and objections submitted in response to 
this notice will not be made available for public inspection, and, to 
the extent permitted by law, will not be released under the Freedom of 
Information Act, 5 U.S.C. 552.

ADDRESSES: Requests for a copy of this patent, inquiries, comments, and 
other materials relating to the contemplated license should be directed 
to Suzanne Seavello Shope, J.D., Technology Licensing and Marketing 
Specialist, Technology Transfer Office, Centers for Disease Control and 
Prevention (CDC), 4770 Buford Highway, Mailstop K-79, Atlanta, GA 
30341, telephone: (770) 488-8613; facsimile: (770) 488-8615.

    Dated: August 31, 2006.
James D. Seligman,
Chief Information Officer, Centers for Disease Control and Prevention.
[FR Doc. E6-14871 Filed 9-7-06; 8:45 am]

BILLING CODE 4163-18-P